Perjeta

Chemical Namepertuzumab
Dosage FormInjection (intravenous; 420 mg/14 mL)
Drug ClassReceptor antagonists
SystemFemale reproductive
CompanyGenentech
Approval Year2012

Indication

  • Indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease
  • Indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
  • Indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Perjeta (pertuzumab) Prescribing Information.2012Genentech Inc., South San Francisco, CA
Document TitleYearSource
Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis. 2022Cancers
Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis.2021Journal of Cancer
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. 2021Future Oncology
Systematic review and meta‑analysis of febrile neutropenia risk with TCH(P) in HER2‑positive breast cancer. 2021Breast Cancer Research and Treatment
Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. 2021CJC Open
Efficacy and safety of anti-HER2 agents in combination with chemotherapy for metastatic HER2-positive breast cancer patient: a network meta-analysis. 2021Frontiers in Oncology
Efficacy and safety of pyrotinib versus T-DM1 in HER2+ metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a Bayesian network meta-analysis. 2021Frontiers in Oncology
The efficacy and safety of additional anti-HER2-targeting drugs in the treatment of HER2-positive advanced breast cancer: a meta-analysis. 2020Anticancer Agents in Medicinal Chemistry
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.2019BMC Cancer
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. 2019Breast Cancer
Epidermal growth factor receptor blockers for the treatment of ovarian cancer (review).2018Cochrane Database of Systematic Reviews
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. 2018Cancer Treatment Reviews
Efficacy and safety of a combination of HER2- targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis. 2017Expert Opinion on Drug Safety